ALCAR.PA
Price:
$0.396
Market Cap:
$24.14M
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It The company was founded in 2008 and is headquartered in Vélizy-Villacoublay, France.
Industry
Medical - Devices
IPO Date
2010-07-13
Stock Exchange
PAR
Ticker
ALCAR.PA
According to Carmat S.A.’s latest financial reports and current stock price. The company's current ROE is 139.64%. This represents a change of 66.81% compared to the average of 83.71% of the last 4 quarters.
The mean historical ROE of Carmat S.A. over the last ten years is -481.88%. The current 139.64% ROE has changed -128.98% with respect to the historical average. Over the past ten years (40 quarters), ALCAR.PA's ROE was at its highest in in the June 2022 quarter at 18.75%. The ROE was at its lowest in in the December 2022 quarter at -1680.28%.
Average
-481.88%
Median
-127.38%
Minimum
-3257.34%
Maximum
450.87%
Discovering the peaks and valleys of Carmat S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 431.60%
Maximum Annual ROE = 450.87%
Minimum Annual Increase = -822.46%
Minimum Annual ROE = -3257.34%
Year | ROE | Change |
---|---|---|
2024 | 100.53% | -15.81% |
2023 | 119.41% | -103.67% |
2022 | -3257.34% | -822.46% |
2021 | 450.87% | -195.36% |
2020 | -472.79% | 169.83% |
2019 | -175.22% | -13.76% |
2018 | -203.18% | 297.68% |
2017 | -51.09% | -35.77% |
2016 | -79.55% | -93.64% |
2015 | -1250.42% | 431.60% |
The current ROE of Carmat S.A. (ALCAR.PA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1012.47%
5-year avg
-611.87%
10-year avg
-481.88%
Carmat S.A.’s ROE is greater than DBV Technologies S.A. (-268.46%), less than Genfit S.A. (1.81%), greater than Cellectis S.A. (-46.10%), less than Nanobiotix S.A. (76.53%), greater than Innate Pharma S.A. (-262.93%),
Company | ROE | Market cap |
---|---|---|
-268.46% | $253.75M | |
1.81% | $161.12M | |
-46.10% | $97.90M | |
76.53% | $221.42M | |
-262.93% | $139.16M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Carmat S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Carmat S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Carmat S.A.'s ROE?
How is the ROE calculated for Carmat S.A. (ALCAR.PA)?
What is the highest ROE for Carmat S.A. (ALCAR.PA)?
What is the 3-year average ROE for Carmat S.A. (ALCAR.PA)?
What is the 5-year average ROE for Carmat S.A. (ALCAR.PA)?
How does the current ROE for Carmat S.A. (ALCAR.PA) compare to its historical average?